Navigation Links
Denis Connaghan Joins Clinverse, Inc. as Chief Executive Officer
Date:8/21/2013

Raleigh, NC (PRWEB) August 21, 2013

Clinverse, Inc., a global technology and eclinical commerce network for clinical trials, announced today the addition of Denis Connaghan as Chief Executive Officer. Denis brings more than 25 years of substantial commercialization experience across industry sectors including technology, healthcare, insurance, life sciences and IT.

Prior to joining Clinverse, Denis served as a management consultant and in interim executive roles at GMA Healthcare, Infina Connect and several other life science IT and services companies. Additionally, he served as the CEO of etrials Worldwide, an eclinical solutions provider to pharmaceutical companies, prior to its acquisition by Merge Healthcare.

“I’m thrilled to join such a fast-paced, growing company,” expressed Connaghan. “Clinverse’s FLS platform is an industry-first and continues to outpace the industry in terms of innovation. We are well positioned to build on this solid technology foundation, and I look forward to working with the Clinverse team to capitalize on my global and industry expertise to drive additional opportunities in the clinical trial services market.”

With the announcement of Denis as CEO, Tim Immel, founder and former CEO of Clinverse, will take on the role of Chief Product Officer. In his new position, Tim will dedicate 100 percent of his commitment and direct attention to pursuing product excellence and ensuring the company maintains and grows its undisputed lead in the area of financial lifecycle systems for the clinical trials industry.

“Of all the many responsibilities I have had at Clinverse, none has been more important to the business or more gratifying to me personally than to design and build the exceptional products and services that we offer, products that fill an important yet unmet need in the marketplace,” said Immel. “Denis’s leadership is critical to our long-term success as we continue taking Clinverse to the heights we all envision, while delivering the highest quality service to clients.”

About Clinverse, Inc.
Clinverse, Inc. is a global technology and financial services company that delivers highly secure, cloud-based financial management and payment solutions for the clinical trials industry. Founded in 2008 and headquartered in Raleigh, NC, the company delivers clinical financial solutions through the only truly collaborative and transparent financial management and payment platform. Used by leading BioPharma companies, Clinverse has developed ClinPay®, a fully-configurable, game-changing SaaS-based platform which manages tens of millions of dollars in financial transactions for thousands of global sites while supporting payments in 140 different currencies. For more information, please visit http://www.clinverse.com.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11041323.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Michael Cusumano, MITs Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors
2. Robert Farrell Joins Bionovos Board of Directors
3. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
4. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
5. First Choice Rehabilitation Specialists Joins Select Medical
6. Excel Life Sciences Joins DATATRAKs Connect Partner Program
7. Marina Biotech, Inc. Joins OTCQX
8. Richard H. Scheuermann, Ph.D. Joins J. Craig Venter Institute as Director of Informatics
9. Dr. David L. Blecker MD, MPH, F.A.C.P. Joins Inergetics Advisory Board to Co-Develop and Market Products to Penetrate Nephrology Market
10. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
11. Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
Breaking Biology News(10 mins):